Why Curanex Pharmaceuticals Inc’s (CURX) Stock Is Down 76.42%
As of Wednesday, September 17, Curanex Pharmaceuticals Inc’s CURX share price has dipped by 76.42%, which has investors questioning if this is right time to buy.Omar Beirat
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients with inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. Curanex Pharmaceuticals Inc was founded in 1996 and is headquartered in Jericho, New York.
Commentary & Analysis
Why Curanex Pharmaceuticals Inc’s (CURX) Stock Is Down 5.64%
As of Monday, September 15, Curanex Pharmaceuticals Inc’s CURX share price has dipped by 5.64%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Curanex Pharmaceuticals Inc’s (CURX) Stock Is Up 5.19%
As of Monday, September 08, Curanex Pharmaceuticals Inc’s CURX share price has surged by 5.19%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Curanex Pharmaceuticals Inc’s (CURX) Stock Is Up 13.44%
As of Thursday, September 04, Curanex Pharmaceuticals Inc’s CURX share price has surged by 13.44%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | CURX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $6.8 | $626.3 | 5% |
|
| Shares Out (Mil) | 1.4 | 43.4 | 6% |
|
| Institutional Ownership | 1.8% | 83.9% | 3% |
|
| Float (Mil) | na | 45.7 | na |
|
| Beta | na | 0.73 | na |
|
| Avg Daily Volume (000s) | 33 | 309 | 25% |
|
| Price Change (52-week) |
(97.3%) | 66.6% | 2% |
|
| Growth | CURX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | na | (1.6%) | na |
|
| EPS (5yr) | na | 15.1% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.0%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | CURX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $317 | na |
|
| Net Income (TTM) (Mil) | ($11) | ($11) | 29% |
|
| EPS (TTM) | ($7.565) | ($0.700) | 6% |
|
| Operating Cash Flow (TTM) (Mil) | ($12) | ($6) | 19% |
|
| Net Cash Flow (TTM) (Mil) | na | $6 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 12% |
|
| Enterprise Value (Q1) (Mil) | $5 | $525 | 5% |
|
| Valuation | CURX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.28 | 2.69 | 32% |
|
| P/E | na | 16.8 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | CURX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.8% | na |
|
| Net Margin | na | (1.4%) | na |
|
| ROA | (357.2%) | (24.1%) | 1% |
|
| ROE | (411.1%) | (21.4%) | 2% |
|
| Liabilities to Assets | 5.6% | 33.1% | 3% |
|
| F-Score | 2 | 3 | 7% |
|
Curanex Pharmaceuticals Inc did not pass any screens on 9/10/2026.
